Morgan Stanley Passage Bio, Inc. Transaction History
Morgan Stanley
- $1.36 Trillion
- Q1 2025
A detailed history of Morgan Stanley transactions in Passage Bio, Inc. stock. As of the latest transaction made, Morgan Stanley holds 6,829 shares of PASG stock, worth $2,868. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,829
Previous 812,442
99.16%
Holding current value
$2,868
Previous $463,000
99.57%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding PASG
# of Institutions
44Shares Held
36.4MCall Options Held
50.3KPut Options Held
0-
Lynx1 Capital Management LP San Juan, PR9.26MShares$3.89 Million1.2% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.03MShares$2.95 Million0.08% of portfolio
-
Vestal Point Capital, LP New York, NY6.1MShares$2.56 Million0.15% of portfolio
-
New Leaf Venture Partners, L.L.C. New York, NY2.5MShares$1.05 Million1.97% of portfolio
-
Erste Asset Management Gmb H Vienna, C42.46MShares$1.03 Million0.01% of portfolio
About Passage BIO, Inc.
- Ticker PASG
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,463,200
- Market Cap $22.9M
- Description
- Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...